Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)
- Authors:
- Emily L. Coleman
- Brianna Olamiju
- Jonathan S. Leventhal
-
Affiliations: Yale School of Medicine, New Haven, CT 06510, USA - Published online on: December 24, 2020 https://doi.org/10.3892/or.2020.7911
- Pages: 891-898
This article is mentioned in:
Abstract
|
National Cancer Institute, . Common terminology criteria for adverse events (CTCAE) v5.0. 2017, https://www.meddra.org/September 5–2018 | |
|
Green MR and Couchman JR: Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol. 85:239–245. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 6:803–812. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rodeck U: Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling? J Cell Physiol. 218:32–34. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC and Los M: Targeting the EGFR pathway for cancer therapy. Curr Med Chem. 13:3483–3492. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fakih M and Vincent M: Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol. 17 (Suppl 1):S18–S30. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S and Smith PD: AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical. Mol Cancer Ther. 6:2209–2219. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M and Smalley KS: The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res. 14:230–239. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Huynh H, Soo KC, Chow PK and Tran E: Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 6:138–146. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 26:2139–2146. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB and Myskowski PL: Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs. 29:1114–1121. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C and Meier F: Immunomodulatory effects of BRAF and MEK inhibitors: Implications for melanoma therapy. Pharmacol Res. 136:151–159. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med. 353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Macdonald JB, Macdonald B, Golitz LE, LoRusso P and Sekulic A: Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 72:203–218. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B and Nistér M: Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52:3213–3219. 1992.PubMed/NCBI | |
|
Seymour L, Dajee D and Bezwoda WR: Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat. 26:247–252. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Smits A, Funa K, Vassbotn FS, Beausang-Linder M, af Ekenstam F, Heldin CH, Westermark B and Nistér M: Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am J Pathol. 140:639–648. 1992.PubMed/NCBI | |
|
Liu KW, Hu B and Cheng SY: Platelet-derived growth factor signaling in human malignancies. Chin J Cancer. 30:581–584. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:994–1004. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Das D, Ganguly S, Deb AR and Aich RK: Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST). J Indian Med Assoc. 111:21–23. 2013.PubMed/NCBI | |
|
Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S and Ravandi F: Philadelphia-positive acute lymphoblastic leukemia: Current treatment options. Curr Oncol Rep. 14:387–394. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pardanani A: Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 90:250–262. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, Schiller M, Hauschild A, Hein R, Kämpgen E, et al: Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: A multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res. 20:499–510. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, et al: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 31:3182–3190. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Koon HB, Krown SE, Lee JY, Honda K, Rapisuwon S, Wang Z, Aboulafia D, Reid EG, Rudek MA, Dezube BJ and Noy A: Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS malignancy consortium protocol 042. J Clin Oncol. 32:402–408. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu FT, Li NG, Zhang YM, Xie WC, Yang SP, Lu T and Shi ZH: Recent advance in the development of novel, selective and potent FGFR inhibitors. Eur J Med Chem. 186:1118842020. View Article : Google Scholar : PubMed/NCBI | |
|
de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J and Prasad V: Estimation of percentage of patients with fibroblast growth factor receptor alterations eligible for off-label use of erdafitinib. JAMA Netw Open. 2:e19160912019. View Article : Google Scholar : PubMed/NCBI | |
|
Katoh M: FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med. 38:3–15. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Helsten T, Elkin S, Arthur E, Tomson BN, Carter J and Kurzrock R: The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 22:259–267. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, et al: Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 45:786–790. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Carr DR, Pootrakul L, Chen HZ and Chung CG: Metastatic calcinosis cutis associated with a selective FGFR inhibitor. JAMA Dermatol. 155:122–123. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, et al: Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer. 13:2622013. View Article : Google Scholar : PubMed/NCBI | |
|
Hou H, Sun D, Liu K, Jiang M, Liu D, Zhu J, Zhou N, Cong J and Zhang X: The safety and serious adverse events of approved ALK inhibitors in malignancies: A meta-analysis. Cancer Manag Res. 11:4109–4118. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sawamura S, Kajihara I, Ichihara A, Fukushima S, Jinnin M, Yamaguchi E, Kohrogi H and Ihn H: Crizotinib-associated erythema multiforme in a lung cancer patient. Drug Discov Ther. 9:142–143. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang S, Wu L, Li X, Huang J, Zhong J and Chen X: Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient. Mol Clin Oncol. 8:457–459. 2018.PubMed/NCBI | |
|
Autier J, Escudier B, Wechsler J, Spatz A and Robert C: Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 144:886–892. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kong HH and Turner ML: Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol. 61:360–361. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Robert C, Sibaud V, Mateus C and Cherpelis BS: Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol. 39:227–240. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM and Pandite L: Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 15:4220–4227. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, et al: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 28:475–480. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hartmann JT and Kanz L: Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 144:1525–1526. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Robert C, Spatz A, Faivre S, Armand JP and Raymond E: Tyrosine kinase inhibition and grey hair. Lancet. 361:10562003. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Coleman EL, Cowper SE, Stein SM and Leventhal JS: Erythema nodosum-like Eruption in the setting of sorafenib therapy. JAMA Dermatol. 154:369–370. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ollech A, Stemmer SM, Merims S, Lotem M, Popovtzer A, Hendler D, Hodak E, Didkovsky E and Amitay-Laish I: Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. Int J Dermatol. 55:473–478. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Choi MK, Woo HY, Heo J, Cho M, Kim GH, Song GA and Kim MB: Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma. Ann Dermatol. 23 (Suppl 3):S404–S407. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K and Iwamura M: Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Urol Int. 91:482–483. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yoon J, Oh CW and Kim CY: Stevens-johnson syndrome induced by vandetanib. Ann Dermatol. 23 (Suppl 3):S343–S345. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pickert A, Hughes M and Wells M: Chloracne-like drug eruption associated with sorafenib. J Drugs Dermatol. 10:1331–1334. 2011.PubMed/NCBI | |
|
Kim DK and Lee SW, Nam HS, Jeon DS, Park NR, Nam YH, Lee SK, Baek YH, Han SY and Lee SW: A case of sorafenib-induced DRESS syndrome in hepatocelluar carcinoma. Korean J Gastroenterol. 67:337–340. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Epskamp C, Snels DGCTM, Yo GL, Zuetenhorst HJ and Hamberg P: Bullous fixed drug eruption in a patient with metastatic renal cell carcinoma induced by iodinated contrast during pazopanib treatment. Eur J Dermatol. 26:207–208. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
MacGregor JL, Silvers DN, Grossman ME and Sherman WH: Sorafenib-induced erythema multiforme. J Am Acad Dermatol. 56:527–528. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Caro-Gutiérrez D, Floristán Muruzábal MU, Gómez de la Fuente E, Franco AP and López Estebaranz JL: Photo-induced erythema multiforme associated with vandetanib administration. J Am Acad Dermatol. 71:e142–e144. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Plan B (levonorgestrel). https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdfAugust 31–2018 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: CYRAMZA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s002lbl.pdfDecember 23–2019 | |
|
Lin WL, Lin WC, Yang JY, Chang YC, Ho HC, Yang LC, Yang CH, Hung SI and Chung WH: Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol. 26:2779–2780. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Urosevic-Maiwald M, Harr T, French LE and Dummer R: Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer. Int J Dermatol. 51:864–867. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pantano F, Silletta M, Iovieno A, Vincenzi B, Santini D, Galluzzo S, Bonini S and Tonini G: Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitunumab. Int J Colorectal Dis. 24:1247–1248. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SS and Chu PY: Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer. Am J Otolaryngol. 31:288–290. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, et al: A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 6:4527–4536. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang JJ, Ma SX, Hou X, Wang Z, Zeng YD, Qin T, Dinglin XX and Chen LK: Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. Chin J Cancer. 34:94–98. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Honda Y, Hattori Y, Katsura S, Terashima T, Manabe T, Otsuka A and Miyachi Y: Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib. Eur J Dermatol. 26:413–414. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Doesch J, Debus D, Meyer C, Papadopoulos T, Schultz ES, Ficker JH and Brueckl WM: Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer. 95:35–38. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wnorowski AM, de Souza A, Chachoua A and Cohen DE: The management of EGFR inhibitor adverse events: A case series and treatment paradigm. Int J Dermatol. 51:223–232. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lamiaux M, Scalbert C, Lepesant P, Desmedt E, Templier C, Dziwniel V, Staumont-Sallé D and Mortier L: Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. Melanoma Res. 28:451–457. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bellón T, Lerma V, González-Valle O, González Herrada C and de Abajo FJ: Vemurafenib-induced toxic epidermal necrolysis: Possible cross-reactivity with other sulfonamide compounds. Br J Dermatol. 174:621–624. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Minor DR, Rodvien R and Kashani-Sabet M: Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib. Melanoma Res. 22:410–411. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Arenbergerova M, Mrazova I, Horazdovsky J, Sticova E, Fialova A and Arenberger P: Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure. J Eur Acad Dermatol Venereol. 31:e253–e254. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jeudy G, Dalac-Rat S, Bonniaud B, Hervieu A, Petrella T, Collet E and Vabres P: Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. Br J Dermatol. 172:1454–1455. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lapresta A, Dotor A and González-Herrada C: Toxic epidermal necrolysis induced by vemurafenib. Actas Dermosifiliogr. 106:682–683. 2015.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI | |
|
Wantz M, Spanoudi-Kitrimi I, Lasek A, Lebas D, Quinchon JF and Modiano P: Vemurafenib-induced toxic epidermal necrolysis. Ann Dermatol Venereol. 141:215–218. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sinha R, Lecamwasam K, Purshouse K, Reed J, Middleton MR and Fearfield L: Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol. 170:997–999. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rosen AC, Balagula Y, Raisch DW, Garg V, Nardone B, Larsen N, Sorrell J, West DP, Anadkat MJ and Lacouture ME: Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 25:225–234. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao PH, Yang CK, Peng MT, Huang CY, Chang WC, et al: Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 10:1259–1273. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wenk KS, Pichard DC, Nasabzadeh T, Jang S and Venna SS: Vemurafenib-Induced DRESS. JAMA Dermatology. 149:12422013. View Article : Google Scholar : PubMed/NCBI | |
|
Munch M, Peuvrel L, Brocard A, Saint Jean M, Khammari A, Dreno B and Quereux G: Early-onset vemurafenib-induced DRESS syndrome. Dermatology. 232:126–128. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gey A, Milpied B, Dutriaux C, Mateus C, Robert C, Perro G, Taieb A, Ezzedine K and Jouary T: Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? J Eur Acad Dermatology Venereol. 30:178–179. 2016. View Article : Google Scholar | |
|
Pinard C, Mignard C, Samain A, Duval-Modeste AB and Joly P: Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib. JAAD Case Reports. 3:532–533. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Brégeon B, Bernier C, Josselin N, Peuvrel L, Moigne ML, Saint-Jean M and Quéreux G: Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases. J Am Acad Dermatol. 80:558–562. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Goldman J, Duval-Modeste AB, Lambert A, Contentin N, Courville P, Musette P and Joly P: Imatinib-induced DRESS. Ann Dermatol Venereol. 135:393–396. 2008.(In French). View Article : Google Scholar : PubMed/NCBI | |
|
Le Nouail P, Viseux V, Chaby G, Billet A, Denoeux JP and Lok C: Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy. Ann Dermatol Venereol. 133:686–688. 2006.(In French). View Article : Google Scholar : PubMed/NCBI | |
|
Kumar M, Mandal PK, Dolai TK and Bhattacharrya M: Imatinib causing drug rash with eosinophilia and systemic symptoms: A rare cutaneous reaction. Indian Dermatol Online J. 5 (Suppl 2):S120–S122. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Saidi W, Lahouel I, Laarif M and Aounallah A: A new case of imatinib-induced drug reaction with eosinophilia and systemic symptoms. Indian J Dermatol Venereol Leprol. 83:2242017. View Article : Google Scholar : PubMed/NCBI | |
|
Ben-Ami E, Castells MC, Connell NT, Rutherford AE and Thornton KA: Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: A patient with dermatofibrosarcoma protuberans and successful desensitization management. Anticancer Drugs. 29:919–923. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Vatel O, Aumont C, Mathy V, Petit M, Feriel J, Sloma I, Bennaceur-Griscelli A and Turhan AG: Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia. Leuk Lymphoma. 58:473–474. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Gilotrif. www.fda.gov/medwatchNovember 13–2019 | |
|
Shih HC, Hsiao YP, Wu MF and Yang JH: Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer. Br J Dermatol. 155:1101–1102. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lakshmi C, Pillai S and Srinivas CR: Lapatinib-induced acute generalized exanthematous pustulosis. Indian Dermatol Online J. 1:14–17. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Brouard MC, Prins C, Mach-Pascual S and Saurat JH: Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology. 203:57–59. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Scott AD, Lee M, Kubba F and Chu A: Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia. Clin Exp Dermatol. 40:926–927. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Schwarz M, Kreuzer KA, Baskaynak G, Dörken B and le Coutre P: Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 69:254–256. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gambillara E, Laffitte E, Widmer N, Decosterd LA, Duchosal MA, Kovacsovics T and Panizzon RG: Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology. 211:363–365. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L and Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 129:92–96. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Schwartz RA, McDonough PH and Lee BW: Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 69:173.e1–e13, 185–186. 2013. View Article : Google Scholar | |
|
Rzany B, Hering O, Mockenhaupt M, Schröder W, Goerttler E, Ring J and Schöpf E: Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 135:6–11. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Harr T and French LE: Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy. 97:149–166. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Erbitux. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htmNovember 13–2019 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Iressa. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdfNovember 13–2019 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Tarceva. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdfNovember 13–2019 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Vectibix® (panitumumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdfNovember 13–2019 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Vizimpro. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdfNovember 13–2019 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: ZELBORAF (Vemurafenib) Tablet for Oral Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdfNovember 13–2019 | |
|
Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW and Sosman JA: Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 1:373–377. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Harding JJ, Pulitzer M and Chapman PB: Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med. 366:866–868. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mahapatra M, Mishra P and Kumar R: Imatinib-induced Stevens-Johnson syndrome: Recurrence after re-challenge with a lower dose. Ann Hematol. 86:537–538. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Pavithran K and Thomas M: Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol. 71:288–289. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bois E, Holle LM and Farooq U: Late onset imatinib-induced Stevens-Johnson syndrome. J Oncol Pharm Pract. 20:476–478. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C and Vegara-Aguilera G: Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood. 101:24462003. View Article : Google Scholar : PubMed/NCBI | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: GLEEVEC (Imatinib Mesylate) Tablets Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdfNovember 13–2019 | |
|
Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, Wang WS, Yen CC and Chen PM: Stevens-Johnson syndrome after treatment with STI571: A case report. Br J Haematol. 117:620–622. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Rule SA, O'Brien SG and Crossman LC: Managing cutaneous reactions to imatinib therapy. Blood. 100:3434–3435. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Jha P, Himanshu D, Jain N and Singh AK: Imatinib-induced Stevens-Johnsons syndrome. BMJ Case Rep. 2013:bcr20120079262013. View Article : Google Scholar : PubMed/NCBI | |
|
Nakamoto K, Nagahara H, Noda E, Inoue T, Maeda K, Ohira G, Amano R, Kubo N, Tanaka H, Muguruma K, et al: Three cases of giant rectal gastrointestinal stromal tumor. Gan To Kagaku Ryoho. 38:1984–1986. 2011.(In Japanese). PubMed/NCBI | |
|
Vidal D, Puig L, Sureda A and Alomar A: Sti571-induced Stevens-Johnson syndrome. Br J Haematol. 119:274–275. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Schaich M, Schäkel K, Illmer T, Ehninger G and Bornhäuser M: Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol. 82:303–304. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh HJ, Chan ALF and Lin SJ: Stevens-Johnson syndrome induced by combination of imatinib and allopurinol. Chemotherapy. 55:197–199. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Severino G, Chillotti C, De Lisa R, Del Zompo M and Ardau R: Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 39:162–164. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Tasigna (Nilotinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdfNovember 13–2019 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Sprycel (Dasatinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdfNovember 13–2019 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: NEXAVAR (Sorafenib) Tablets, for Oral Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdfNovember 13–2019 | |
|
U.S. Food and Drug Administration, . Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing information: Caprelsa (Vandetanib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022405s007lbl.pdfNovember 13–2019 | |
|
Szatkowski J and Schwartz RA: Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 73:843–848. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Choudhary S, McLeod M, Torchia D and Romanelli P: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 6:31–37. 2013.PubMed/NCBI | |
|
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L and Roujeau JC: The DRESS syndrome: A literature review. Am J Med. 124:588–597. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M and Roujeau JC; RegiSCAR study group, : Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 169:1071–1080. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, Wechsler J, de Feraudy S, Duong TA, Delfau-Larue MH, Chosidow O, Wolkenstein P and Roujeau JC: Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: A morphological and phenotypical study. Br J Dermatol. 173:50–58. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, Chosidow O and Valeyrie-Allanore L: Therapeutic management of DRESS: A retrospective study of 38 cases. J Am Acad Dermatol. 72:246–252. 2015. View Article : Google Scholar : PubMed/NCBI |
